KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Accured Expenses: 2013-2015

  • Teva Pharmaceutical Industries' Change in Accured Expenses was N/A to $1.3 billion in Q3 2015 from the same period last year, while for Sep 2015 it was $4.3 billion, marking a year-over-year change of. This contributed to the annual value of $258.0 million for FY2024, which is 83.75% down from last year.
  • According to the latest figures from Q3 2015, Teva Pharmaceutical Industries' Change in Accured Expenses is $1.3 billion, which was down 3.21% from $1.4 billion recorded in Q4 2014.
  • In the past 5 years, Teva Pharmaceutical Industries' Change in Accured Expenses ranged from a high of $1.4 billion in Q4 2013 and a low of $1.3 billion during Q3 2015.
  • In the last 3 years, Teva Pharmaceutical Industries' Change in Accured Expenses had a median value of $1.4 billion in 2014 and averaged $1.4 billion.
  • Data for Teva Pharmaceutical Industries' Change in Accured Expenses shows a maximum YoY decreased of 0.89% (in 2014) over the last 5 years.
  • Quarterly analysis of 3 years shows Teva Pharmaceutical Industries' Change in Accured Expenses stood at $1.4 billion in 2013, then fell by 0.89% to $1.4 billion in 2014, then reached $1.3 billion in 2015.
  • Its last three reported values are $1.3 billion in Q3 2015, $1.4 billion for Q4 2014, and $1.4 billion during Q4 2013.